+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Biogen

  • ID: 5357337
  • Company Profile
  • January 2021
  • 45 pages
  • Datamonitor Healthcare
  • Biogen Inc.
The publisher explores Biogen’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Biogen’s prescription pharmaceutical business will see stable performance over the medium term.
  • Key themes - [1] Biogen’s flagship MS portfolio - Tecfidera, Avonex, Plegridy, and Tysabri - remains incredibly stable [2] Spinraza revenues will plateau during the forecast period due to competition from newer products [3] Biogen’s revival of aducanumab is a surprise and will add significant revenue during the forecast period.
Model updates (21 October 2020)
  • Tecfidera forecast adjusted lower due to generic competition in the US
  • Spinraza forecast adjusted lower due to competition in the US
  • Vumerity forecast adjusted higher due to better launch trend in the US
  • Aducanumab forecast adjusted higher due to refinement of Alzheimer’s disease market potential and launch trends.
Model updates (22 July 2020)
  • Tecfidera forecast adjusted significantly lower due to litigation outcome resulting in earlier generic competition
  • Vumerity forecast adjusted lower due to later expected launch in EU and RoW
  • Imraldi forecast adjusted lower in EU.
Model updates (22 April 2020)
  • Vumerity forecast adjusted lower due to continued slow launch.
Model updates (30 January 2020)
  • Spinraza forecast adjusted higher due to continued international growth
  • Avonex forecast adjusted lower due to continued competition in multiple sclerosis
  • Vumerity forecast adjusted lower due to initial launch trends.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll